Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms

William G. Ondo, Kapil Dev Sethi, Greg Kricorian

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease. Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable "wearing off" and "on-off" fluctuations. METHODS: We conducted a 12-week, double-blind, placebo-controlled, parallel-design trial of selegiline ODT. The primary efficacy point was reduction in the percentage of average daily "off" time. Secondary measures included reductions in daily off hours and total daily off time, Clinical Global Impressions- Improvement (CGI-I), and Patient Global Impression-Improvement (PGI-I). Patients on LD received selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks) or placebo. Safety and tolerability were measured. RESULTS: The intent-to-treat population included 98 patients receiving selegiline ODT and 50 patients receiving placebo. Combined efficacy results for weeks 10 and 12 revealed an 11.6% reduction in percentage of daily off time for selegiline ODT versus a 9.8% reduction for placebo (NS). PGI-I detected a statistically significant difference between treatment groups in favor of selegiline ODT (P = 0.02), whereas CGI-I detected a strong trend toward improvement (P = 0.06). Selegiline ODT was safe and well tolerated. CONCLUSIONS: This study showed no significant difference in improvement in percentage of off time with selegiline ODT versus placebo. Some clinical impressions (e.g., PGI-I, CGI-I) improved. This result contrasts with an identically designed study that showed a significant improvement in off time with selegiline ODT. A combined analysis of both studies suggested overall efficacy.

Original languageEnglish (US)
Pages (from-to)295-300
Number of pages6
JournalClinical Neuropharmacology
Volume30
Issue number5
DOIs
StatePublished - Sep 1 2007

Fingerprint

Selegiline
Tablets
Parkinson Disease
Levodopa
Placebos
Monoamine Oxidase Inhibitors
Monoamine Oxidase

Keywords

  • Clinical trial
  • Levodopa
  • Parkinson disease
  • Selegiline
  • Zydis

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. / Ondo, William G.; Sethi, Kapil Dev; Kricorian, Greg.

In: Clinical Neuropharmacology, Vol. 30, No. 5, 01.09.2007, p. 295-300.

Research output: Contribution to journalArticle

Ondo, William G. ; Sethi, Kapil Dev ; Kricorian, Greg. / Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. In: Clinical Neuropharmacology. 2007 ; Vol. 30, No. 5. pp. 295-300.
@article{072a57a5f60949608410f0aaa6fa2e87,
title = "Selegiline orally disintegrating tablets in patients with Parkinson disease and {"}wearing off{"} symptoms",
abstract = "BACKGROUND: Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease. Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable {"}wearing off{"} and {"}on-off{"} fluctuations. METHODS: We conducted a 12-week, double-blind, placebo-controlled, parallel-design trial of selegiline ODT. The primary efficacy point was reduction in the percentage of average daily {"}off{"} time. Secondary measures included reductions in daily off hours and total daily off time, Clinical Global Impressions- Improvement (CGI-I), and Patient Global Impression-Improvement (PGI-I). Patients on LD received selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks) or placebo. Safety and tolerability were measured. RESULTS: The intent-to-treat population included 98 patients receiving selegiline ODT and 50 patients receiving placebo. Combined efficacy results for weeks 10 and 12 revealed an 11.6{\%} reduction in percentage of daily off time for selegiline ODT versus a 9.8{\%} reduction for placebo (NS). PGI-I detected a statistically significant difference between treatment groups in favor of selegiline ODT (P = 0.02), whereas CGI-I detected a strong trend toward improvement (P = 0.06). Selegiline ODT was safe and well tolerated. CONCLUSIONS: This study showed no significant difference in improvement in percentage of off time with selegiline ODT versus placebo. Some clinical impressions (e.g., PGI-I, CGI-I) improved. This result contrasts with an identically designed study that showed a significant improvement in off time with selegiline ODT. A combined analysis of both studies suggested overall efficacy.",
keywords = "Clinical trial, Levodopa, Parkinson disease, Selegiline, Zydis",
author = "Ondo, {William G.} and Sethi, {Kapil Dev} and Greg Kricorian",
year = "2007",
month = "9",
day = "1",
doi = "10.1097/WNF.0b013e3180616570",
language = "English (US)",
volume = "30",
pages = "295--300",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms

AU - Ondo, William G.

AU - Sethi, Kapil Dev

AU - Kricorian, Greg

PY - 2007/9/1

Y1 - 2007/9/1

N2 - BACKGROUND: Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease. Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable "wearing off" and "on-off" fluctuations. METHODS: We conducted a 12-week, double-blind, placebo-controlled, parallel-design trial of selegiline ODT. The primary efficacy point was reduction in the percentage of average daily "off" time. Secondary measures included reductions in daily off hours and total daily off time, Clinical Global Impressions- Improvement (CGI-I), and Patient Global Impression-Improvement (PGI-I). Patients on LD received selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks) or placebo. Safety and tolerability were measured. RESULTS: The intent-to-treat population included 98 patients receiving selegiline ODT and 50 patients receiving placebo. Combined efficacy results for weeks 10 and 12 revealed an 11.6% reduction in percentage of daily off time for selegiline ODT versus a 9.8% reduction for placebo (NS). PGI-I detected a statistically significant difference between treatment groups in favor of selegiline ODT (P = 0.02), whereas CGI-I detected a strong trend toward improvement (P = 0.06). Selegiline ODT was safe and well tolerated. CONCLUSIONS: This study showed no significant difference in improvement in percentage of off time with selegiline ODT versus placebo. Some clinical impressions (e.g., PGI-I, CGI-I) improved. This result contrasts with an identically designed study that showed a significant improvement in off time with selegiline ODT. A combined analysis of both studies suggested overall efficacy.

AB - BACKGROUND: Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease. Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable "wearing off" and "on-off" fluctuations. METHODS: We conducted a 12-week, double-blind, placebo-controlled, parallel-design trial of selegiline ODT. The primary efficacy point was reduction in the percentage of average daily "off" time. Secondary measures included reductions in daily off hours and total daily off time, Clinical Global Impressions- Improvement (CGI-I), and Patient Global Impression-Improvement (PGI-I). Patients on LD received selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks) or placebo. Safety and tolerability were measured. RESULTS: The intent-to-treat population included 98 patients receiving selegiline ODT and 50 patients receiving placebo. Combined efficacy results for weeks 10 and 12 revealed an 11.6% reduction in percentage of daily off time for selegiline ODT versus a 9.8% reduction for placebo (NS). PGI-I detected a statistically significant difference between treatment groups in favor of selegiline ODT (P = 0.02), whereas CGI-I detected a strong trend toward improvement (P = 0.06). Selegiline ODT was safe and well tolerated. CONCLUSIONS: This study showed no significant difference in improvement in percentage of off time with selegiline ODT versus placebo. Some clinical impressions (e.g., PGI-I, CGI-I) improved. This result contrasts with an identically designed study that showed a significant improvement in off time with selegiline ODT. A combined analysis of both studies suggested overall efficacy.

KW - Clinical trial

KW - Levodopa

KW - Parkinson disease

KW - Selegiline

KW - Zydis

UR - http://www.scopus.com/inward/record.url?scp=34848857679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848857679&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3180616570

DO - 10.1097/WNF.0b013e3180616570

M3 - Article

C2 - 17909308

AN - SCOPUS:34848857679

VL - 30

SP - 295

EP - 300

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -